00:17:50 EST Sun 15 Dec 2019
Enter Symbol
or Name
USA
CA



Login ID:
Password:
Save
Cognetivity Neurosciences Ltd
Symbol CGN
Shares Issued 41,447,022
Close 2019-05-02 C$ 0.37
Recent Sedar Documents

Cognetivity names Brougham commercial development head

2019-05-02 11:09 ET - News Release

Mr. Sina Habibi reports

COGNETIVITY NEUROSCIENCES APPOINTS DIGITAL HEALTH SPECIALIST TO DRIVE PLATFORM COMMERCIALIZATION STRATEGY & SALES

Cognetivity Neurosciences Ltd. has appointed digital health specialist Rob Brougham as its head of commercial development.

Mr. Brougham is an astrophysicist by training with a successful 20-year commercial career in telecom and digital health care in both blue chip and entrepreneurial roles. He entered the digital health market as it first emerged and was the chief executive officer of British Telecom's digital health business and subsequently the United Kingdom managing director of Ieso digital health, a company delivering digital mental health care solutions through the Web.

With a specialism in commercial acceleration, Mr. Brougham has worked as a senior digital health adviser and consultant supporting both early-stage and multinational corporations, and brings a proven record of delivering significant transactions worth over one billion pounds.

Mr. Brougham will be tasked with leading Cognetivity's commercial strategy and platform sales in both clinical and enterprise markets, and will also join the company's U.K. subsidiary, Cognetivity Ltd., board as a director.

"Having witnessed incredible innovation within digital health over the last decade, I firmly believe Cognetivity's platform is up there with the very best I've seen," said Mr. Brougham. "To me it signals a legitimate industry step change, not only for how early and effectively dementia can be detected but also in the opportunities it provides to those working on developing effective long-term treatments. The ICA platform addresses a major unmet global market and this, combined with Cognetivity's world class technological approach, presents a significant commercial opportunity. I'm exceptionally excited to work with the incredible Cognetivity team and do my best to ensure the platform generates revenue for the company, and is made available to as many people as possible."

Cognetivity's CEO Sina Habibi said: "Rob has an exceptionally strong and proven track record of delivering major revenue and profit growth for a string of high-profile organizations in the area of digital health. We're excited to welcome him to the team and have him lead our commercial development, and to help drive the commercialization of our platform."

About Cognetivity Neurosciences Ltd.

Cognetivity is a technology company developing a cognitive testing platform, the Integrated Cognitive Assessment, for use in medical, commercial and consumer environments. Cognetivity's ICA uses artificial intelligence and machine learning techniques to help detect the earliest signs of impairment by testing the performance of large areas of the brain, potentially allowing early diagnosis of dementia.

We seek Safe Harbor.

© 2019 Canjex Publishing Ltd. All rights reserved.